Description: Helix BioMedix, Inc. is a specialty dermatology and consumer products skin health company, which is engaged in developing bioactive peptides for uses across a range of markets. The Company focuses on developing topically-applied products, which offer the health, beauty and safety benefits of its bioactive small molecule technology. The Company is engaged in developing topical anti-infectives for the treatment of skin and wound infections, and the prevention of Staphylococcus aureus (S. aureus) infections, including those caused by Methicillin-resistant Staphylococcus aureus (MRSA). The Company's programs are based upon a family of molecules known as lipohexapeptides (or small molecule peptides) that it has developed to specifically combine the attributes of small molecule natural products with the advantages of antimicrobial peptides. The Company's lipohexapeptides (HB1345 and HB1275) do not exhibit cross-resistance with other antibiotics.
Home Page: www.helixbiomedix.com
22121-17th Avenue SE
Bothell,
WA
98021
United States
Phone:
425-402-8400
Officers
| Name | Title |
|---|---|
| Ms. Robin L. Carmichael | President, CEO & Director |
| Kelly Forsythe | Associate Director of Marketing |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.3231 |
| Price-to-Sales TTM: | 1.6696 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |